Related Experiment Video
Updated: Sep 13, 2025

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
Published on: August 30, 2018
Incidence of Acute Kidney Injury in Critically Ill Patients Receiving Vancomycin With Concomitant
Abstract:
Objectives: To explore whether vancomycin (VAN) plus piperacillin-tazobactam (PTZ) was associated with an increased risk of acute kidney injury (AKI) compared with VAN plus other beta-lactams (BLs) or monotherapy in critically ill patients, where the evidence remains controversial. Data sources: PubMed, Cochrane, Web of Science, and Embase were searched from inception to June 2024. Study selection: Studies comparing the risk of AKI with one group receiving VAN+PTZ, and other groups receiving VAN plus other BLs, or monotherapy in critically ill. Data synthesis: This analysis included 20 articles with 28 243 participants. The majority of included studies were retrospective (95%, 19/20) and had moderate risks of bias (80.0%, 16/20). The results indicated VAN+PTZ was associated with a significantly higher risk of AKI compared with VAN plus other BLs (OR = 1.66, 95% CI = 1.42-1.94, P < 0.001). Subgroup analyses showed that compared with adults, children were associated with a higher risk of AKI when receiving VAN+PTZ (OR = 3.16 vs 1.59). Also, VAN+PTZ was associated with a significantly higher risk of severe stage 2 to 3 AKI than VAN plus other BLs (OR = 1.63, 95% CI = 1.28-2.06, P < 0.001). No significant difference was identified in mortality, dialysis, time to AKI, and length of stay between patients receiving VAN plus PTZ and other combinations. Conclusions: In critically ill, VAN plus PTZ was associated with an increased risk of AKI and severe stage 2 to 3 AKI compared with VAN plus other BLs, especially in children. However, more high-quality multicenter, prospective cohort studies, and randomized controlled studies are needed.
Insights
Vancomycin plus piperacillin-tazobactam (PTZ) increases acute kidney injury (AKI) risk in critically ill patients compared to other beta-lactams. Children are at higher risk, necessitating further high-quality research.
Area of Science:
- Critical Care Medicine
- Nephrology
- Pharmacology
Background:
- Evidence regarding the association between vancomycin (VAN) plus piperacillin-tazobactam (PTZ) and acute kidney injury (AKI) in critically ill patients is conflicting.
- This combination is frequently used, highlighting the need for clarity on its nephrotoxic potential.
Purpose of the Study:
- To investigate the risk of AKI associated with VAN plus PTZ compared to VAN plus other beta-lactams (BLs) or monotherapy in critically ill patients.
- To identify patient subgroups, such as children, who may be at increased risk.
Main Methods:
- A systematic search of major databases (PubMed, Cochrane, Web of Science, Embase) was conducted up to June 2024.
- Included studies compared AKI risk in critically ill patients receiving VAN+PTZ versus VAN+other BLs or monotherapy.
- Meta-analysis of 20 retrospective studies involving 28,243 participants was performed.
Main Results:
- VAN plus PTZ was significantly associated with a higher risk of AKI compared to VAN plus other BLs (OR = 1.66).
- Children demonstrated a markedly higher risk of AKI with VAN+PTZ compared to adults (OR = 3.16 vs 1.59).
- VAN plus PTZ was linked to a greater risk of severe stage 2 to 3 AKI (OR = 1.63).
Conclusions:
- Vancomycin plus piperacillin-tazobactam is associated with an increased risk of AKI and severe AKI in critically ill patients, particularly in children.
- No significant differences in mortality, dialysis, time to AKI, or length of stay were observed.
- High-quality, multicenter, prospective cohort, and randomized controlled studies are required to confirm these findings.
Related Concept Videos
Acute Pyelonephritis II: Diagnostic Studies and Management
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury V: Interprofessional Care
Acute Kidney Injury I: Introduction
Acute Kidney Injury III: Clinical Manifestations
Acute Kidney Injury II: Pathophysiology

